close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

1.920 +0.100 (+5.49%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy Pipeline 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
Late-breaking poster presentation to highlight new immunogenicity data from ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.